Skip to content

SW · NOVN.SW · DRUG MANUFACTURERS - GENERAL

Novartis AG (NOVN.SW) intrinsic value and stock valuation

$127.76as of 2026-11-21 · Mkt cap 226.76B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Novartis AG DCF and intrinsic value

InvestorsCraft values NOVN.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NOVN.SW’s statements →

Novartis AG Graham Number

Graham Number: $63.86d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Basel 4056 novartis.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$57.1B+2.7% 5y CAGRd
20112025
Net income
$14.6B+12.7% 5y CAGRd
20112025
Free cash flow
$18.4B+10.7% 5y CAGRd
20112025
Total equity
$46.5B-3.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$57.1B$51.7B$46.7B$43.5B$44B
Operating income$17.8B$14.5B$9.77B$7.95B$10.1B
Net income$14.6B$11.9B$14.9B$6.96B$24B
EPSd$7.49M$5.87M$7.1M$3.17M$10.6M
Operating cash flow$20.1B$17.6B$14.5B$14.2B$15.1B
Capital expenditure-$-1.62B-$-3.81B-$-2.75B-$-2.67B-$-2.97B
Free cash flow$18.4B$13.8B$11.7B$11.6B$12.1B
Total assets$115.5B$102.2B$99.9B$117.5B$131.8B
Total debt$37B$31.3B$26.3B$27.9B$31B
Net debt$25.6B$19.8B$13B$20.4B$18.6B
Total equity$46.5B$44.1B$46.8B$59.4B$67.8B
Cash and short-term investments$11.6B$13.4B$14B$18.6B$28.1B
Income statement
20252024202320222021
Revenue$57.1B$51.7B$46.7B$43.5B$44B
Cost of revenue$14.3B$12.8B$12.5B$11.6B$11.7B
Gross profit$42.9B$38.9B$34.2B$31.9B$32.2B
Research and development expenses$11.2B$10B$11.4B$9.17B$8.64B
Selling, general and administrative expenses$13.9B$12.6B$12.5B$12.2B$12.8B
Other expenses$0.00$1.76B$531M$2.57B$715M
Operating expenses$25.1B$24.4B$24.4B$23.9B$22.2B
Cost and expenses$39.3B$37.2B$36.9B$35.5B$33.9B
Interest income$390.8M$550.8M$658.5M$389.3M$71M
Interest expense$1.24B$1.01B$916.9M$860.2M$904.8M
Depreciation and amortization$5.58B$6.07B$8.28B$6.71B$5.6B
Ebitda$24B$20.7B$18.3B$14.7B$30.9B
Operating income$17.8B$14.5B$9.77B$7.95B$10.1B
Total other income/expenses, net-$-665.21M-$-904M-$-646M-$-769M$14.5B
Income before tax$17.1B$13.6B$9.12B$7.18B$24.5B
Income tax expense$2.5B$1.7B$551M$1.13B$1.63B
Net income$14.6B$11.9B$14.9B$6.96B$24B
Weighted average shares outstanding$1.94B$2.02B$2.09B$2.18B$2.24B
Weighted average diluted shares outstanding$1.96B$2.04B$2.09B$2.2B$2.26B
Balance sheet
20252024202320222021
Cash and short-term investments$11.6B$13.4B$14B$18.6B$28.1B
Net receivables$10.9B$9.54B$9.38B$9.89B$9.62B
Inventory$6.26B$5.72B$5.91B$7.18B$6.67B
Total current assets$30.4B$29.7B$30.5B$36.9B$45.7B
Property, plant and equipment, net$12.3B$10.9B$10.9B$12.2B$13.1B
Goodwill and intangible assets$54.9B$51.7B$50.2B$60.9B$63.8B
Long-term investments$2.3B$1.13B$1.83B$1.61B$2.27B
Total non-current assets$85.1B$72.5B$69.5B$80.5B$86.1B
Total assets$115.5B$102.2B$99.9B$117.5B$131.8B
Accounts payable$4.45B$4.57B$4.93B$5.15B$5.55B
Short-term debt$5.78B$8.32B$6.31B$6.13B$6.5B
Deferred revenue$0.00$127M$98M$123M$123M
Total current liabilities$27.3B$28.7B$26.4B$28.7B$30.2B
Long-term debt$31.2B$22.9B$20B$21.8B$24.5B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$41.7B$29.4B$26.8B$29.4B$33.8B
Capital lease obligations$1.92B$1.8B$1.83B$1.79B$1.9B
Total liabilities$69B$58.1B$53.2B$58B$64B
Common stock$765.5M$793M$825M$890M$901M
Retained earnings$44.7B$46.6B$49.6B$63.5B$71B
Accumulated other comprehensive income (loss)$693.5M-$-3.25B-$-3.7B-$-5B-$-4.17B
Total equity$46.5B$44.1B$46.8B$59.4B$67.8B
Total investments$2.46B$3.02B$2.4B$12.7B$18B
Total debt$37B$31.3B$26.3B$27.9B$31B
Net debt$25.6B$19.8B$13B$20.4B$18.6B
Cash flow statement
20252024202320222021
Net income$14.6B$11.9B$8.57B$6.96B$24B
Depreciation and amortization$5.58B$6.07B$8.28B$7.18B$6.11B
Stock-based compensation$0.00$1.04B$865M$791M$700M
Change in working capital-$-3.21B-$-706M-$-369M-$-1B$241M
Accounts receivable-$-1.18B-$-931M-$-1.5B-$-589M-$-389M
Inventory$35.6M-$-225M-$-546M-$-830M$81M
Accounts payable-$-285.99M-$-105M$479M-$-48M-$-21M
Net cash provided by operating activities$20.1B$17.6B$14.5B$14.2B$15.1B
Investments in property, plant and equipment-$-4.09B-$-1.37B-$-1.06B-$-2.67B-$-2.97B
Acquisitions, net-$-3.13B-$-3.92B-$-3.56B-$-903M$20.1B
Net cash used for investing activities-$-5.11B-$-7.51B$5.6B$1.47B$4.21B
Common stock issued$28.3M$0.00$0.00$0.00$53M
Common stock repurchased-$-9.65B-$-8.33B-$-8.72B-$-10.65B-$-3.06B
Dividends paid-$-8.19B-$-7.62B-$-7.26B-$-7.51B-$-7.37B
Net cash used for financing activities-$-15.57B-$-11.74B-$-14.28B-$-20.56B-$-16.26B
Net change in cash-$-1.67B-$-1.93B$5.88B-$-4.89B$2.75B
Cash at end of period$11.4B$11.5B$13.4B$7.52B$12.4B
Operating cash flow$20.1B$17.6B$14.5B$14.2B$15.1B
Capital expenditure-$-1.62B-$-3.81B-$-2.75B-$-2.67B-$-2.97B
Free cash flow$18.4B$13.8B$11.7B$11.6B$12.1B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Novartis AG

        Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

        CEO
        Vasant Narasimhan
        Employees
        75.88K
        Beta
        0.49

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Novartis AG (NOVN.SW)?

        InvestorsCraft does not currently publish an intrinsic value for NOVN.SW. How the IC value is calculated.

        Is NOVN.SW undervalued?

        InvestorsCraft does not publish an undervaluation signal for NOVN.SW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.